文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

氨基糖苷类与卷曲霉素治疗耐多药结核:25国12030例个体数据Meta分析

Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016.
PubMed 文献 · Clin Infect Dis · 2021-01-01

结果显示链霉素和阿米卡星优于卡那霉素与卷曲霉素,后两者并不优于不用注射剂。

要点

  • 药敏支持时,链霉素和阿米卡星是MDR-TB注射剂首选,而非卡那霉素或卷曲霉素。
  • 与卡那霉素相比,阿米卡星每100例多6例治愈(95%CI 4-8)。
  • 与卷曲霉素相比,链霉素每100例多10例治愈(95%CI 8-13)、少10例死亡(95%CI 7-12)。

核心结论

  • 在药敏试验结果支持所用药物时,治疗MDR-TB应选用链霉素或阿米卡星,而非卡那霉素或卷曲霉素。

研究设计与样本

  • 分析基于分离株对所接受药物敏感的患者,采用倾向评分匹配的随机效应logistic回归估计各药物对标准化治疗结局的效应。

主要发现

  • 接受卡那霉素者4330例、卷曲霉素者2401例,多于阿米卡星2275例和链霉素1554例,与其表观疗效相反。
  • 与卡那霉素相比,阿米卡星每100例多6例治愈(95%CI 4-8),链霉素每100例多7例治愈(95%CI 5-8)、少5例死亡(95%CI 4-7)。
  • 与卷曲霉素相比,阿米卡星每100例多9例治愈(95%CI 6-11)、少5例死亡(95%CI 2-8);链霉素每100例多10例治愈(95%CI 8-13)、少10例死亡(95%CI 7-12)。
  • 接受卡那霉素或卷曲霉素的患者结局不优于未用注射剂者,而阿米卡星和链霉素则优于不用注射剂。

临床怎么用

  • 在药敏结果支持的前提下,MDR-TB注射剂方案应优先选择链霉素或阿米卡星,避免以卡那霉素或卷曲霉素替代。

局限性

  • 分析仅纳入分离株对所用药物敏感的患者,未覆盖耐药人群,且为观察性个体数据合并,存在混杂可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As new drugs are developed for multidrug-resistant tuberculosis (MDR-TB), the role of currently used drugs must be reevaluated. METHODS: We combined individual-level data on patients with pulmonary MDR-TB published during 2009-2016 from 25 countries. We compared patients receiving each of the injectable drugs and those receiving no injectable drugs. Analyses were based on patients whose isolates were susceptible to the drug they received. Using random-effects logistic regression with propensity score matching, we estimated the effect of each agent in terms of standardized treatment outcomes. RESULTS: More patients received kanamycin (n = 4330) and capreomycin (n = 2401) than amikacin (n = 2275) or streptomycin (n = 1554), opposite to their apparent effectiveness. Compared with kanamycin, amikacin was associated with 6 more cures per 100 patients (95% confidence interval [CI], 4-8), while streptomycin was associated with 7 (95% CI, 5-8) more cures and 5 (95% CI, 4-7) fewer deaths per 100 patients. Compared with capreomycin, amikacin was associated with 9 (95% CI, 6-11) more cures and 5 (95% CI, 2-8) fewer deaths per 100 patients, while streptomycin was associated with 10 (95% CI, 8-13) more cures and 10 (95% CI, 7-12) fewer deaths per 100 patients treated. In contrast to amikacin and streptomycin, patients treated with kanamycin or capreomycin did not fare better than patients treated with no injectable drugs. CONCLUSIONS: When aminoglycosides are used to treat MDR-TB and drug susceptibility test results support their use, streptomycin and amikacin, not kanamycin or capreomycin, are the drugs of choice.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cegielski JP, Chan PC, Lan Z, et al. Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016. Clin Infect Dis. 2021. PMID: 33124668. doi:10.1093/cid/ciaa621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。